A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro

I Inoue, T Nakajima, C S Williams, J Quackenbush, R Puryear, M Powers, T Cheng, E H Ludwig, A M Sharma, A Hata, X Jeunemaitre, J M Lalouel, I Inoue, T Nakajima, C S Williams, J Quackenbush, R Puryear, M Powers, T Cheng, E H Ludwig, A M Sharma, A Hata, X Jeunemaitre, J M Lalouel

Abstract

In earlier studies, we provided statistical evidence that individual differences in the angiotensinogen gene, the precursor of the vasoactive hormone angiotensin II, constitute inherited predispositions to essential hypertension in humans. We have now identified a common variant in the proximal promoter, the presence of an adenine, instead of a guanine, 6 bp upstream from the initiation site of transcription, in significant association with the disorder. Tests of promoter activity and DNA binding studies with nuclear proteins suggest that this nucleotide substitution affects the basal transcription rate of the gene. These observations provide some biological insight about the possible mechanism of a genetic predisposition to essential hypertension; they may also have important evolutionary implications.

References

    1. Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
    1. Am J Hum Genet. 1962 Dec;14:353-62
    1. J Clin Invest. 1986 Jul;78(1):31-9
    1. J Biol Chem. 1986 Aug 5;261(22):10375-9
    1. J Biol Chem. 1989 Mar 25;264(9):5047-52
    1. Gene. 1989 Apr 15;77(1):51-9
    1. Nucleic Acids Res. 1989 Aug 11;17(15):6419
    1. J Biol Chem. 1990 May 5;265(13):7576-82
    1. J Cardiovasc Pharmacol. 1987;10 Suppl 7:S1-8
    1. Nature. 1992 Jan 16;355(6357):262-5
    1. Anal Biochem. 1992 Mar;201(2):255-64
    1. Cell. 1992 Oct 2;71(1):169-80
    1. Nat Genet. 1993 May;4(1):59-61
    1. Nat Genet. 1993 Jun;4(2):114-5
    1. FEBS Lett. 1993 Aug 30;329(3):233-7
    1. Nucleic Acids Res. 1993 Aug 11;21(16):3623-9
    1. J Clin Invest. 1994 Mar;93(3):1285-7
    1. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2629-33
    1. J Clin Invest. 1994 Apr;93(4):1370-9
    1. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3612-5
    1. Cell. 1994 Nov 4;79(3):407-14
    1. J Clin Invest. 1995 Mar;95(3):948-53
    1. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2735-9
    1. J Biol Chem. 1995 May 12;270(19):11430-6
    1. Nat Genet. 1995 Aug;10(4):394-9
    1. Nat Med. 1995 Oct;1(10):994-6
    1. Nat Med. 1995 Oct;1(10):1009-16
    1. J Biol Chem. 1996 Jul 5;271(27):15981-6
    1. J Hypertens. 1996 Feb;14(2):199-207
    1. J Mol Biol. 1984 Aug 15;177(3):531-57

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren